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Abstract 
Prostaglandin E I(PGE 1) inhibits tyrosine phosphorylation induced by low thrombin concentration (0.05 U/ml), but this 
is overcome by a high thrombin (2.0 U/ml) concentration. Thromboxane A 2 and ADP are endogenous platelet agonists 
released uring platelet activation which potentiate platelet responses. We investigated how these endogenous agonists 
influenced the effects of PGE 1 on thrombin (2.0 U/ml)-induced tyrosine pbosphorylation by removing released ADP with 
apyrase (2.0 U/ml) and by inhibiting thromboxane A 2 synthesis with indomethacin (1 I~M). Adding PGE 1 (1 txM) before 
tbrombin in apyrase/indomethacin(A/I)-treated plat lets electively prevented thrombin-induced tyrosine phosphorylation 
of a 117 kDa protein while other substrates were not affected. This selective ffect was evident only in the presence of 
apyrase and was not dependent on indomethacin. Addition of PGE 1 to A/I-treated platelets after thrombin also caused 
selective tyrosine dephosphorylation of the 117 kDa protein. Conditions which prevented thrombin-induced 117 kDa protein 
tyrosine phosphorylation also decreased fibrinogen binding to platelets. The 117 kDa protein was identified as the focal 
adhesion kinase (FAK) by immunoprecipitation with a monoclonal antibody to FAK and by absence of its tyrosine 
phosphorylation in the presence of RGDS peptide which inhibits fibrinogen binding and platelet aggregation. Thus, released 
endogenous ADP selectivel[y prevents PGEl-mediated tyrosine dephosphorylation of platelet FAK most likely by stabilizing 
fibrinogen binding to platelets. 
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1. Introduction 
A variety of physiologic agonists can activate 
platelets by interacting vAth their receptors to turn on 
common signal transduction pathways [1]. This cas- 
cade of events includes G-protein activation, increase 
Abbreviations: PGE l, prostaglandin El; IP 3, inositol-l,4,5- 
phosphate; FAK, focal adhesion kinase. 
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in turnover of inositol phospholipids, elevation of 
cytosolic calcium and activation of protein kinases. 
These events culminate in platelet shape change, 
secretion of storage granule contents, expression of 
new surface antigens and aggregation. With strong 
activation the platelet agonist ADP is released from 
dense granules while the agonist hromboxane A z is 
synthesized and released into the medium. These 
agonists can further potentiate the platelet responses 
by acting through their own platelet receptors. 
Platelet activation is also associated with increased 
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tyrosine phosphorylation of proteins [2]. Certain 
platelet responses uch as aggregation [3], inositol 
turnover [4,5] and calcium influx [6] appear to be 
dependent on tyrosine phosphorylation since they are 
prevented by tyrosine kinase inhibitors. Thus, under- 
standing the regulation of protein tyrosine phosphory- 
lation may offer insight into molecular mechanisms 
of platelet reactivity. 
The prevailing level of tyrosine phosphorylation is 
dependent on the dynamic balance between activities 
of tyrosine kinases and opposing tyrosine phos- 
phatases. We have previously demonstrated that tyro- 
sine phosphorylation and dephosphorylation f cer- 
tain platelet proteins, including the cytoskeletal pro- 
tein vinculin [7], is controlled by levels of calcium in 
separate subcellular compartments [8]. Another set of 
proteins, which includes the focal adhesion kinase 
(FAK), is tyrosine phosphorylated when fibrinogen 
binds and crosslinks its platelet receptor, glycoprotein 
IIb/IIIa (integrin ~iib[~3) [2,9]. However, it is not yet 
clear how this interaction tips the balance towards 
their tyrosine phosphorylated state or what is the 
significance of additional tyrosine phosphorylation in 
an already aggregated platelet. 
An important clue which may help unravel the 
controlling mechanisms of tyrosine phosphorylation 
has been the observation that thrombin-induced tyro- 
sine phosphorylation can be prevented when platelets 
are pretreated with agents like prostaglandin E~ 
(PGE 1) which elevate platelet cAMP [10-12]. We 
have found that with high thrombin concentrations 
the released endogenous agonist, ADP, specifically 
prevents PGEl-induced ephosphorylation of FAK. 
2. Methods 
2.1. Platelet isolation 
500000/txl. Divalent cations (MgCI 2 0.5 mM and 
CaC12 2.0 mM) were added to the filtered platelets 
and the cells were equilibrated at room temperature 
for 30 min prior to start of experiments. 
2.2. Detection of tyrosine phosphorylation 
Gel-filtered platelets (0.5 ml) were activated with 
thrombin (2 U/ml) and the reaction was stopped 
after 3 min by adding the platelet mixture to an equal 
volume of boiling SDS-PAGE buffer (0.125 Tris-HC1, 
4% SDS, 20% glycerol, pH 6.8) and heating for 2 
min. PGE 1 was added 3 min prior to thrombin. 
Protein tyrosine phosphorylation was detected on im- 
munoblots of whole platelet proteins separated by 
SDS-PAGE on 7.5% mini-gels as previously de- 
scribed [8]. The primary antibody was a monoclonal 
antibody to phosphotyrosine (clone 4G10) (UBI, Lake 
Placid, NY) and the secondary antibody was anti- 
mouse IgG linked to alkaline phosphatase (Boeh- 
ringer, Indianapolis, IN). 
2.3. Detection of tyrosine dephosphorylation 
Gel-filtered platelets were activated with thrombin 
(2 U/ml) to induce tyrosine phosphorylation. 3 min 
later, this platelet suspension was divided into equal 
volumes and PGE 1 (1 IxM) was added to one of 
these. Platelets were then sampled at 5, 10 and 20 
min to determine the extent of tyrosine phosphoryla- 
tion. For experiments using the arginine-glycine- 
aspartic acid-serine (RGDS) peptide (2 mM, Sigma, 
St. Louis, MO), the starting platelet suspension was 
divided and RGDS was added to one half prior to 
addition of thrombin to both. 
2.4. Measurement ofcytosolic alcium elevation with 
Fluo 3-AM 
Platelet-rich plasma (PRP) was obtained from 
healthy volunteer donors by apheresis. 10 ml of PRP 
was treated with 1 I~M PGE 1 and the platelets were 
separated from plasma proteins by gel filtration on a 
Sepharose 2B column equilibrated with 
Tyrode's/Hepes buffer (in mM: NaC1 138, KC1 2.9, 
NaH2CO 3 12, NaH2PO 4 0.4, dextrose 5.0, Hepes 
5.0, BSA, Fraction V, fatty acid-free 0.35%, pH 7.4). 
Collected platelets were diluted to a count of 
Stock solution of acetomethoxy ester (AM) form 
of the fluorescent calcium indicator dye Fluo 3 
(Molecular Probes, Eugene, OR) was prepared by 
mixing 1 mM Fluo 3-AM in dimethyl sulfoxide with 
Pluronic detergent (Molecular Probes) in a ratio of 19 
parts Fluo 3-AM to 1 part Pluronic and frozen at 
-20°C. The stock suspension was diluted to 10 p~M 
with Tyrode's buffer and mixed with an equal vol- 
ume of gel-filtered platelets in Tyrode's buffer with 
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0.35% BSA (no CaC12 or MgC12). The final platelet 
count was 2 × 10 6 cells/ml. Cells were incubated in 
the dark at 37°C for 30 rain after which 2 mM GaG12 
and 0.5 mM MgC12 were added. Due to low back- 
ground fluorescence, the platelets were not washed 
prior to detection of fluorescence at room tempera- 
ture by flow cytometry (FACScan, Becton Dicken- 
son, San Jose, CA) with excitation at 488 nm and 
emission at 530 nm. Platelet fluorescence was sam- 
pled every 5 s and analyzed with Chronys 1.1.2 
software (Becton Dickenson). Cytosolic calcium con- 
centrations were estimated based on the dissociation 
constant (K d) of Fluo 3 which is 400 nM at 22°C, 
and determination f Fma x with 1 i.LM A23187 in 2 
mM CaC12 and Fmi n with 1 IxM A23187 in presence 
of 6 mM EGTA [13]. 
2.5. Immunoprecipitation f FAK 
Gel-filtered and apyrase/indomethacin-treated 
platelets were activated with thrombin (2 U/ml)  for 
5 min with or without PGE 1 (1 ~M) pretreatment. 10
min after addition of thrombin, platelets were lysed 
by the addition of equal volume of lysis buffer which 
contained in mM NaC1 50, EGTA 5, Hepes 5, CHAPS 
2%, pH 7.2, and the following protease inhibitors in 
Ixg/ml: leupeptin 1, antipain 2, benzamidine 10, 
chymotrypsin hibitor 2, pepstatin 2, and PMSF 200 
~M. Platelet lysate (0.5 ml) was pre-cleared for 4 h 
at 4°C with 50 ixl of agarose-protein G suspension 
previously washed 4 titmes with lysis buffer. The 
cleared lysate was centrifuged at 2000 X g for 1 min 
and the supernate was transferred to 25 ~1 of washed 
agarose-protein G. A monoclonal antibody to FAK 
(Transduction Labs, Lexington, KY) was added (10 
~g in 10 ~1) and precipitation was carried out at 4°C 
overnight. Agarose-protein G was then separated from 
the lysate by centrifugation at 2000 X g for 1 min 
and washed 4 times with 0.5 ml lysis buffer and 
centrifugation. The final pellet was resuspended in 50 
Ixl SDS-PAGE buffer with 1% [3-mercaptoethanol 
and heated at 95°C for 2 min. Proteins were separated 
on SDS-PAGE and tyrosine phosphorylation was de- 
tected by immunoblotting as described above. 
2.6. Fibrinogen binding studies 
Fibrinogen (Grade L, Kabi, Stockholm, Sweden) 
was labeled with fluorescein isothiocyanate (FITC) 
using the Quick Tag FITC Conjugation Kit (Boeh- 
ringer Mannheim, Indianapolis, IN) according to the 
manufacturer's in tructions. The molar fluorescein to 
protein ratio was 7.5 as determined spectrophotomet- 
rically and calculated using a modification of the 
method escribed by Th6 and Feltkamp [14]. FITC- 
fibrinogen was 94% clottable. FITC-fibrinogen (100 
ix g/ml) was added to platelets (10 000/ix l) in modi- 
fied Tyrode's buffer along with the peptide glycine- 
proline-arginine-proline (GPRP, 2 mM, Sigma) to 
prevent the polymerization of fibrin generated by 
thrombin [15]. Platelets treated with indomethacin (1 
IxM) or apyrase/indomethacin (2 U/ml,  1 ~M, re- 
spectively) were activated with thrombin (2 U/ml)  
with or without prior addition of PGE 1 (1 ~M). The 
platelets were immediately analyzed using a flow 
cytometer with the excitation at 488 nm and emission 
at 530 nm. Results were quantitated by comparing the 
mean channel fluorescence of individual histograms. 
2.7. Quantitation of platelet cAMP 
Gel-filtered platelets (500000/ixl) were treated 
with 1 txM indomethacin for 10 min and divided into 
equal volumes. Apyrase (2 U/ml)  was added to one 
half. 1 ml of the platelet suspensions was then treated 
either with PGE 1 (1 ~M) or thrombin (2 U/ml)  for 5 
min or with PGE 1 (1 ~M) for 5 min followed by 
thrombin (2 U/ml)  for 5 min. At the end of incuba- 
tions 2 ml of ice-cold ethyl alcohol was added to 
each one ml of platelet suspension and the tubes were 
placed on ice for 10 min. The tubes were then 
centrifuged at 10000Xg for 10 min to remove 
precipitates. The supernates were collected, evapo- 
rated to dryness at 60°C under a stream of helium gas 
and the residue was resuspended in 600 lxl of assay 
buffer provided in a cAMP enzyme immunoassay kit 
(Amersham, Buckinghamshire, UK). The cAMP con- 
tent of the samples was analyzed with this kit accord- 
ing to manufacturer's in tructions. 
3. Results 
Activation of gel-filtered, non-stirred platelets with 
low concentration thrombin (0.05 U/ml)  is associ- 
ated with increased tyrosine phosphorylation primar- 
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Fig. 1. Effects of PGE= on thrombin-induced platelet yrosine phosphorylation. Gel-filtered platelets were treated with or without PGE 1 (1 
I~M) 3 min prior to activation with thrombin (0.05 or 2.0 U/ml) and were sampled 3 min after addition of thrombin. In one lane PGE~ 
was added 3 min after thrombin and platelets were sampled 3 min later. Tyrosine phosphorylation was detected on immunoblots of whole 
platelets with antiphosphotyrosine antibody as described in Section 2. Arrows identify proteins mentioned in Section 3. Blot is 
representative of 4 separate xperiments. TH = thrombin, PGE = PGE I. 
ily of  120 and 85 kDa proteins and to a lesser extent 
of  95 and 70 kDa proteins (Fig. 1). The onset of  
thrombin- induced tyrosine phosphorylat ion occurs 
within 15-30  s [8]. Pretreatment of  platelets with 1 
txM PGE l, which elevates platelet cAMP levels 
through receptor-mediated activation of  adenylate cy- 
clase [16], does not change tyrosine phosphorylat ion 
in resting platelets but prevents the appearance of  
thrombin- induced tyrosine phosphorylation. When 
PGE 1 (1 txM) is added to platelets already activated 
kDa 
200 
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Fig. 2. Effects of indomethacin a d apyrase on thrombin-induced tyrosine phosphorylation in PGEl-treated platelets. Gel-filtered platelets 
were treated with indomethacin (1 IxM), apyrase (2 U/ml) or both for 15 min. Platelet suspension was then divided and PGE l (1 p~M) 
was added to one half prior to addition of thrombin (2 U/ml) to both of them. Tyrosine phosphorylation was determined 3 min later. Blot 
is representative of 3 experiments. Arrow identifies a tyrosine phosphorylated 117 kDa protein. Indo = indomethacin, TH = thrombin. 
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Fig. 3. Effect of PGE 1 on cytosolic calcium elevation. 
Thrombin-induced cytosolic calcium was estimated by f low cy- 
tometry in gel filtered platele~ts loaded with Fluo 3 /AM (Section 
2). Control platelets were treated with PGE 1 (1 ~M) for 3 min 
prior to addition of thrombin (0.05 or 2.0 U/ml).  Indomethacin 
(1 txM) and apyrase (2 U/ml)  were added 15 min prior to 
addition of PGE] and agonist. Data are expressed as % of 
maximal calcium response to thrombin (2 U/ml)  and are a mean 
of 4 experiments___ SEM. Indo = Indomethacin, apy = apyrase, 
PGE = PGE]. 
with thrombin for 3 rain, it does not decrease the 
tyrosine phosphorylation when platelets are sampled 
3 min later (Fig. 1). 
Increasing the thrombin concentration to 2.0 U /ml  
induces tyrosine phosphorylation of a greater number 
of proteins including those with molecular masses of 
120-117, 100, 95, 85, 70 and 60 kDa. The phosphory- 
lation induced by this thrombin concentration is not 
blocked or decreased by pretreatment of platelets 
with 1 txM PGE 1 (Fig. 1). 
3.1. Role of ADP and thromboxane A 2 in mediating 
cAMP inhibition of tyrosine phosphorylation 
Platelet activation is accompanied by generation of 
thromboxane A 2 and secretion of stored ADP [1]. 
These agonists can interact with their receptors to 
further potentiate or modify the platelet response to 
the original activating agonist. To test whether these 
second agonists played a role in PGE~-induced inhi- 
bition of tyrosine phosphorylation, we incubated 
platelets with apyrase, an enzyme which hydrolyzes 
ADP, or indomethacin, an inhibitor of thromboxane 














Fig. 4. Effects of apyrase, PGE~ and thrombin on platelet cAMP levels. Indomethacin (1 ixM)-treated platelets were treated for 5 min 
with PGE 1 (1 ~M) or thrombin (2 U/ml)  or PGE 1/for 5 min followed by thrombin for another 5 min with or without apyrase (2 U/ml).  
cAMP levels were determined as described in Section 2 and are the means _ SE of 3 separate xperiments, apy = apyrase, TH = thrombin, 
PGE = PGE i. 
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Fig. 5. PGE~-induced tyrosine dephosphorylation of 117 kDa protein in apyrase/indomethacin-treated and thrombin-activated platelets. 
(Upper panel) Platelets were activated with thrombin (2.0 U/ml) for 3 min and then either treated with or without PGE~ (1 ~M). 
Tyrosine phosphorylation was determined at indicated times. Arrow indicates tyrosine phosphorylated 117 kDa protein. (Lower panel) 
Platelets treated with apyrase (2 U/ml)/indomethacin (1 p.M) were activated with thrombin (2.0 U/ml) for 3 min and then either treated 
with or without PGE 1 (1 IxM). Blots are representative of 3 experiments. Arrow indicates tyrosine dephosphorylated 117 kDa protein. 
Fig. 6. (A) Effect of PGE 1 on FITC-fibrinogen binding to thrombin-activated platelets. Indomethacin (1 IxM, upper panel)-treated or 
indomethacin (1 txM)/apyrase (2 U/ml, lower panel)-treated platelets were incubated with FITC-fibrinogen, activated with thrombin (2 
U/ml) and platelet-associated fluorescence was determined immediately by flow cytometry (Section 2). Where indicated, PGE 1 (1 IxM) 
was added 3 min before thrombin. The y-axis represents he number of events (platelets) counted for each level of fluorescence on the 
x-axis. The data from a single experiment is representative of 3 separate xperiments. (B) Effect of RGDS peptide on thrombin-induced 
tyrosine phosphorylation f a 117 kDa protein. Apyrase (2 U/ml)/indomethacin (1 txM)-treated platelets were activated with thrombin 
(2.0 U/ml) for 3 min, divided in half and PGE 1 was added to one half. Tyrosine phosphorylation was determined 20 min later. Where 
indicated, RGDS (2 raM) was added 2 min prior to thrombin. Blot is representative of 3 experiments. 
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thrombin-induced tyrosine phosphorylation in un- 
treated cells to apyrase-, indomethacin- or 
apyrase/indomethacin-treated cells. These inhibitors, 
when added alone or together, did not change the 
tyrosine phosphorylation profile induced by thrombin 
(2.0 U/ml) .  Pretreating with PGE 1 also did not 
change the response induced by thrombin in control 
or indomethacin-treated c lls. In comparison, when 
apyrase was present, either alone or with indo- 
methacin, PGE 1 selectively prevented thrombin-in- 
duced tyrosine phosphorylation f a 117 kDa protein. 
3.2. Effects of PGE 1 on platelet cytosolic calcium 
Tyrosine phosphorylation of specific platelet pro- 
teins depends on elevation of cytosolic alcium [8,17]. 
We tested whether the inhibitory effect of cAMP on 
tyrosine phosphorylation i platelets could be sec- 
ondary to cAMP-mediated decrease of agonist-in- 
duced calcium elevation. Gel-filtered platelets were 
loaded with the fluorescent calcium indicator dye, 
Fluo-3/AM, and the level of cytosolic alcium eleva- 
tion was followed by flow cytometry in resting and 
thrombin-activated platelets. High concentration of 
thrombin (2.0 U /ml )  elevated cytosolic calcium to 
approximately 700 to 800 nM. Calcium responses of 
other agonists were standardized against the high 
concentration thrombin response which was taken as 
100%. 
Low concentration thrombin induced 79% of the 
maximal response, and this was decreased to less 
than 10% with PGE 1 (Fig. 3). Apyrase/indomethacin 
treatment did not change the response to low concen- 
tration thrombin but, as occurred in untreated 
platelets, PGE 1 prevented low thrombin concentra- 
tion-induced cytosolic calcium rise. With high con- 
centration thrombin, PGE 1 decreased the calcium re- 
sponse to 76%. In apyrase/indomethacin-treated 
platelets, the high concentration thrombin response 
was decreased to 77%, and this was further decreased 
to 62% with PGE 1 pretreatment. 
3.3. Changes in platelet cAMP levels with PGE 1 
treatment 
Cyclic AMP levels were measured in resting and 
PGEl-treated platelets (Fig. 4). Resting cells had 0.9 
nmol cAMP/1011 cells and this increased to 2.64 
nmol cAMP/10 ll cells with PGE l treatment. Activa- 
tion with thrombin (2 U/ml )  did not change cAMP 
levels from resting state but decreased the elevation 
induced by PGE l to 1.02 nmol cAMP/10 ll cells. In 
the presence of apyrase (2 U /ml )  the cAMP levels in 
response to PGE 1 were strongly potentiated to 10.05 
nmol cAMP/10 ll cells. With apyrase, thrombin (2 
U/ml )  decreased the PGE 1 induced cAMP levels to 
6.09 nmol cAMP/1011 cells. 
3.4. PGEl-induced dephosphorylation i  absence of 
endogenous ADP 
We tested whether PGE 1 prevented only tyrosine 
phosphorylation f the 117 kDa protein or whether it 
also caused its dephosphorylation in apyrase-treated 
platelets. Untreated or apyrase/indomethacin-treated 
platelets were first activated with thrombin (2 U/ml) .  
After 3 min, when tyrosine phosphorylation was es- 
tablished, the cells were divided; one half was left 
untreated while PGE 1 was added to the other half, 
and tyrosine phosphorylation was followed over time. 
Tyrosine phosphorylation of a 117 kDa protein was 
maintained for 20 min in thrombin-activated platelets 
whether they were treated with apyrase/indo- 
methacin or not. Adding PGE~ to thrombin-activated 
untreated cells did not induce dephosphorylation (Fig. 
5A), but adding PGE 1 to apyrase/indomethacin- 
treated cells caused a rapid dephosphorylation f a 
117 kDa protein (Fig. 5B). 
3.5. Identification of tyrosine phosphorylated and 
dephosphorylated 117 kDa protein as Focal Adhe- 
sion Kinase (FAK) 
Tyrosine phosphorylation of a protein in the 120 
kDa range suggested that this protein may be in the 
group of proteins that are tyrosine phosphorylated as
a result of fibrinogen binding and platelet aggregation 
[2,9]. We initially tested whether the conditions which 
prevent tyrosine phosphorylation of the 117 kDa 
protein also affected fibrinogen binding to thrombin 
(2.0 U/ml)-activated platelets. In indomethacin- 
treated platelets, thrombin induced an increase in 
cell-associated FITC-fibrinogen fluorescence, and this 
was only slightly decreased with PGE 1 pretreatment 
(94.4 + 4.5% of thrombin-induced fluorescence, 
mean ___ range, n = 2). With apyrase/indomethacin- 
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treated platelets, PGE 1 pretreatment decreased the 
amount of thrombin-induced fibrinogen binding to 
22.5 _ 9.7% (mean _ SEM, n = 3) (Fig. 6A). 
To determine whether fibrinogen binding was re- 
quired for the tyrosine phosphorylation of the 117 
kDa protein, we activated the platelets in the presence 
of 2 mM RGDS peptide which blocks fibrinogen 
binding and platelet aggregation [18]. The IC50 for 
this peptide in preventing fibrinogen binding to acti- 
vated platelets is 18 p.M with > 90% of binding 
inhibited at 200 IxM [19]. Apyrase/indomethacin- 
treated platelets, with or without RGDS, were acti- 
vated with high concentration thrombin. After 3 min 
the activated platelets were again divided as de- 
scribed above, one half was treated with PGE 1 and 
the extent of tyrosine phosphorylation was deter- 
mined 20 min later (Fig 6B). In absence of RGDS, a 
117 kDa protein was tyrosine phosphorylated as be- 
fore, and addition of PGE 1 reversed the tyrosine 
phosphorylation by 20 min. In presence of RGDS, 
the 117 kDa protein was; not tyrosine phosphorylated. 
A 125 kDa platelet protein whose tyrosine phos- 
phorylation is dependent on platelet fibrinogen bind- 
ing and aggregation is the focal adhesion kinase 
(FAK) [20]. The relative molecular weight of FAK 
has been reported as 125 kDa [20] but under our 
conditions it migrates on SDS-PAGE gels as a 117 
kDa protein, below tyrosine phosphorylated vinculin 
(120 kDa) [7] and in line with the 117 kDa molecular 
weight standard, 13-galactosidase (Pre-stained SDS- 
PAGE standards, Bio-Rad, Hercules, CA). Fig. 7A is 
a blot of indomethacin/apyrase treated platelets acti- 
vated with thrombfn with or without PGE 1 pretreat- 
ment. The blot was then cut in half in the middle of a 
lane and developed with anti-phoshotyrosine or anti- 
FAK. The lane cut in half shows that FAK migrates 
with the 117 kDa protein which is tyrosine phospho- 
rylated or dephosphorylated depending on the pres- 
ence of apyrase and PGE I. To confirm that FAK is 
tyrosine phosphorylated and dephosphorylated with 
PGE1 we prepared lysates from indo-  
methacin/apyrase-treated platelets in either throm- 
bin-activated or PGEl-pretreated and thrombin- 
activated states. Immunoprecipitation f these lysates 
with a monoclonal antiFAK antibody isolated equal 
amounts of a 117 kDa protein from both lysates. 
Developing these blots with antiphosphotyrosine 
demonstrated FAK was tyrosine phosphorylated in
A anti-Phosphotyrosine anti-FAK 
PGE1 + + 
TH + + + + 
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Fig. 7. (A) Migration of focal adhesion kinase (FAK) and of the 
tyrosine phosphorylated 117 kDa protein on SDS-PAGE. Apyrase 
(2 U/ml)/indomethacin (1 i~M)-treated cells were activated 
with thrombin (2.0 U/ml) for 3 min with or without PGE 1, 
separated on SDS-PAGE and blotted. The blot was cut in half 
(lane 3) and one half was developed with anti-phosphotyrosine 
and the other with anti-FAK. Arrow indicates FAK. TH = 
thrombin, PGE/TH = PGEl-treated and TH-activated. (B) Tyro- 
sine phosphorylation of focal adhesion kinase (FAK) immunopre- 
cipitated from lysates of thrombin-activated platelets. Apyrase (2 
U/ml)/indomethacin (1 ixM)-treated cells were activated with 
thrombin (2.0 U/ml) for 3 min with or without PGE 1 and lysed 
as described in Section 2. Lysates were immunoprecipitated with 
monoclonal antibody to FAK, proteins were separated on 
SDS/PAGE gels, immunoblotted and developed with anti-phos- 
photyrosine antibody and anti-FAK. Arrow indicates FAK. Blot 
is representative of 3 experiments. TH = thrombin, PGE/TH = 
PGEl-treated and TH-activated. 
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thrombin-activated platelets but not in PGEl-pre- 
treated and thrombin-activated cells (Fig. 7B). 
4. Discussion 
PGE 1 induces a rise in platelet cAMP levels as is 
evident in Fig. 4 and as has been reported by others 
[10-12]. Many consequences of cAMP elevation in 
platelets involve inhibition of steps in the agonist-in- 
duced signal transduction pathways which lead to a 
rise in cytosolic calcium. Cyclic AMP decreases 
affinity of the platelet thrombin receptor [21], de- 
creases phospholipase C activation and the amount of 
IP 3 generated [21,22] and lowers the affinity of the 
IP 3 receptor [23]. Moreover, cAMP also increases the 
rate of removal of cytosolic calcium by activating 
membrane calcium ATPases [24]. Thus elevation of 
cAMP prior to platelet activation can totally prevent 
thrombin-induced cytosolic calcium elevation as is 
demonstrated in Fig. 3 with Fluo-3 loaded platelets 
and as has been reported previously [25]. Since the 
effects of cAMP are realized through decrease in 
affinities of reactions in a second messenger generat- 
ing cascade, higher amounts of second messengers 
can overcome this inhibition. This is evident in the 
ability of high concentrations of thrombin to over- 
come the effects of PGE~ treatment and to increase 
cytosolic calcium and restore tyrosine phosphoryla- 
tion to levels found in control platelets. 
Platelets contain a variety of cytosolic tyrosine 
kinases including members of the src family, p60src, 
fyn, lyn, yes and hck [26] and others like FAK [27] 
and syk [28]. The regulatory mechanisms for their 
activities may include elevation of cytosolic calcium 
since this is sufficient for tyrosine phosphorylation f 
some proteins in platelets [8,17]. Cytosolic calcium 
may activate tyrosine kinases directly or indirectly 
through other calcium-sensitive enzymes uch as pro- 
tein kinase C (PKC) [29]. Elevation of cytosolic 
calcium may also act by mediating the rearrangement 
of cytosolic proteins to bring tyrosine kinases physi- 
cally together with appropriate substrates. During 
activation, platelet p60src is translocated from the 
cytosol to the cytoskeleton [11,30,31] and some cyto- 
skeletal proteins, such as vinculin which is a p60src 
substrate in other cells [32], are tyrosine phosphory- 
lated in the early stages of platelet activation [7]. A 
likely effect of cAMP, particularly with low concen- 
tration of thrombin, is that it prevents cytosolic cal- 
cium elevation and the rearrangement of cytosolic 
proteins that is associated with it, thus preventing 
kinase and substrate interaction. 
Tyrosine phosphorylation i duced by high concen- 
tration of thrombin is not decreased by PGE 1. One 
tyrosine phosphorylated substrate, a 117 kDa protein, 
does not get tyrosine phosphorylated if PGEI is 
present and extracellular ADP is removed. We have 
identified this protein as FAK based on 1) its identi- 
cal migration with FAK on SDS-PAGE gels 2) im- 
munoprecipitation f FAK with a monoclonal anti- 
body and demonstration that FAK has decreased 
tyrosine phosphorylation in platelets treated with 
apyrase-thrombin-PGE 1 and 3) the finding that tyro- 
sine phosphorylation of the 117 kDa protein and of 
FAK [33] can be prevented by RGDS which blocks 
fibrinogen binding to platelets and aggregation [19]. 
Besides FAK there is also the possibility that addi- 
tional tyrosine phosphorylated proteins make up the 
117 kDa band. This possibility is less likely since 
tyrosine phosphorylation f such proteins would also 
have to be controlled by ADP and PGE x, since the 
tyrosine phosphorylated 117 kDa band can fully dis- 
appear under these conditions. 
In the absence of secreted endogenous ADP, 
thrombin-induced tyrosine phosphorylation f FAK is 
more sensitive to the inhibitory effects of PGE 1 than 
is cytosolic calcium elevation, which suggests that 
the point(s) through which PGE~ and ADP control 
FAK tyrosine phosphorylation is downstream of the 
calcium response. One such downstream event is the 
exposure of an active state of glycoprotein I Ib/I I Ia 
which binds fibrinogen and mediates platelet aggre- 
gation. Tyrosine phosphorylation of FAK requires 
fibrinogen binding to platelets but this alone is not 
sufficient, and additional signals resulting from cross- 
linking of the glycoprotein l ib/ I l ia  molecules by 
fibrinogen in the plane of the plasma membrane or by 
crosslinking adjacent platelets, as in aggregation, are 
also needed [34]. As is shown in Fig. 6, removal of 
ADP and treatment with PGE 1 decreases thrombin- 
induced fibrinogen binding to platelets while PGE~ 
alone does not. ADP has been shown to increase 
platelet fibrinogen binding [35], while elevation of 
cAMP can decrease fibrinogen binding to glyco- 
protein I Ib/I I Ia [36]. Moreover, agonist-induced ag- 
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gregation already in progress and the fibrinogen bind- 
ing associated with it cart be reversed at their peak by 
addition of agents which elevate cAMP [37]. With 
high concentrations of t]hrombin used in our experi- 
ments fibrinogen-mediated platelet microaggregates 
may be formed even in the absence of stirring [2]. It 
is therefore likely that the opposite ffects of released 
ADP and PGE~ on tyrosine phosphorylation of FAK 
are due to their effects on fibrinogen binding to 
glycoprotein l ib / I l i a  in thrombin-activated platelets. 
The released ADP eithe.r directly contributes to the 
stabilization of the glycoprotein I Ib / l l Ia  complex in 
its active state capable., of binding fibrinogen or, 
indirectly, released ADP decreases PGE~-induced in- 
crease in cAMP which mediates desaggregation a d 
tyrosine dephosphorylation f FAK. ADP can achieve 
this by activating the Gi2 G-protein to inhibit adeny- 
late cyclase [38]. The higher cAMP levels reached in 
absence of ADP may prevent the glycoprotein 
l ib / I l i a  complex from reaching the active state capa- 
ble of binding fibrinogen. 
The physiological significance of this observation 
is supported by the report that endothelial cells have 
ecto-ADPase activity which can hydrolyze released 
platelet ADP [39]. Endothelial cells also produce 
prostacyclin which, like PGE~, increases platelet 
cAMP [40]. Thus, fibrinogen binding to glycoprotein 
l ib / I l i a  and the subsequent FAK phosphorylation i  
a fully activated platelet can be specifically prevented 
by endothelial cells through removal of ADP and 
release of prostacyclin. 
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